Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tü 6075. I. Taxonomy, fermentation, isolation and biological activities.

Literature DB >> 12195962

Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tü 6075. I. Taxonomy, fermentation, isolation and biological activities.

Judith Schimana¹, Klaus Gebhardt, Alexandra Höltzel, Dietmar G Schmid, Roderich Süssmuth, Johannes Müller, Rüdiger Pukall, Hans-Peter Fiedler.

Abstract

New lipopeptide antibiotics, colourless arylomycins A series and yellow arylomycins B series were detected in the culture filtrate and mycelium extracts of Streptomyces sp. Tü 6075 by HPLC-diode-array and HPLC-electrospray-mass-spectrometry screening. Arylomycins are a family of lipohexapeptide antibiotics, which represent the first examples of biaryl-bridged lipopeptides. They show antibiotic activities against Gram-positive bacteria.

Entities: Chemical Species

Mesh：

Substances：

Year: 2002 PMID： 12195962 DOI： 10.7164/antibiotics.55.565

Source DB: PubMed Journal: J Antibiot (Tokyo) ISSN： 0021-8820 Impact factor: 2.649

Keyword Cloud
Cited

32 in total

1. Initial efforts toward the optimization of arylomycins for antibiotic activity.

Authors: Tucker C Roberts; Mark A Schallenberger; Jian Liu; Peter A Smith; Floyd E Romesberg
Journal: J Med Chem Date: 2011-06-28 Impact factor: 7.446

Review 2. Protein export systems of Mycobacterium tuberculosis: novel targets for drug development?

Authors: Meghan E Feltcher; Jonathan Tabb Sullivan; Miriam Braunstein
Journal: Future Microbiol Date: 2010-10 Impact factor: 3.165

3. Type I signal peptidase and protein secretion in Staphylococcus epidermidis.

Authors: Michael E Powers; Peter A Smith; Tucker C Roberts; Bruce J Fowler; Charles C King; Sunia A Trauger; Gary Siuzdak; Floyd E Romesberg
Journal: J Bacteriol Date: 2010-11-12 Impact factor: 3.490

Review 4. The inhibition of type I bacterial signal peptidase: Biological consequences and therapeutic potential.

Authors: Arryn Craney; Floyd E Romesberg
Journal: Bioorg Med Chem Lett Date: 2015-07-26 Impact factor: 2.823

5. In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci.

Authors: Peter A Smith; Michael E Powers; Tucker C Roberts; Floyd E Romesberg
Journal: Antimicrob Agents Chemother Date: 2010-12-28 Impact factor: 5.191

Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tü 6075. I. Taxonomy, fermentation, isolation and biological activities.

1. Initial efforts toward the optimization of arylomycins for antibiotic activity.

Review 2. Protein export systems of Mycobacterium tuberculosis: novel targets for drug development?

3. Type I signal peptidase and protein secretion in Staphylococcus epidermidis.

Review 4. The inhibition of type I bacterial signal peptidase: Biological consequences and therapeutic potential.

5. In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci.

6. Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

Review 7. Oxidative Cyclization in Natural Product Biosynthesis.

8. Type I signal peptidase and protein secretion in Staphylococcus aureus.

9. Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition.

Review 10. Development of novel drugs from marine surface associated microorganisms.